A decade ago, "seeing a doctor" meant a waiting room. Now weight loss medication, therapy, hair loss treatment, hormone care and birth control are routinely handled through an app — and a small ecosystem of excellent podcasts has emerged to track how healthcare quietly moved online. These are the shows that explain what's happening behind the interface, and the fights worth following.
Why telehealth became the story of the decade
The pandemic gets the credit, but it only opened the door; three forces drove the industry through it. First, GLP-1 weight loss drugs created consumer demand on a scale traditional clinics couldn't absorb — online prescribing filled the gap so successfully that telehealth companies became some of the drugs' largest distribution channels, and the fight over compounded versions (legal during official shortages, then aggressively contested by the drugmakers once shortages ended) became one of the defining business battles in healthcare. Second, mental health demand permanently outran the supply of in-person therapists, pushing therapy onto platforms — with growing pains, most famously the controversy over aggressive ADHD prescribing at startup Cerebral, and the FTC's multimillion-dollar action against BetterHelp for sharing user health data with advertisers. Third, a generation that manages everything by phone simply expected healthcare to follow, and men in particular — historically the least likely to book appointments — turned out to be willing patients when the door was a questionnaire about hair, ED or testosterone rather than a clinic visit. The result is a genuine restructuring of care delivery, with all the access gains and incentive problems that implies.
The shows
The Heart of Healthcare
Halle Tecco founded Rock Health — the first dedicated digital health venture fund — and has spent fifteen years at the center of the industry as investor, founder and educator. Her podcast interviews the founders and operators building (and sometimes breaking) the companies reshaping care delivery, and she's candid in a way industry insiders rarely are on tape: which startup models are real medicine, which are regulatory arbitrage, and why US healthcare's incentives produce both. The episodes on direct-to-consumer prescribing economics are the best primer available on how this industry actually makes money.
Second Opinion
Christina Farr covered health tech as a journalist at Reuters, Fast Company and CNBC before crossing into venture investing, and her Second Opinion newsletter-and-podcast franchise brings a reporter's skepticism the space badly needs. Her coverage of the GLP-1 gold rush — telehealth prescribing standards, the compounding fight, what happens when the company selling the drug also employs the prescriber — is the sharpest available in audio, and she's equally good on the mental-health platform reckoning.
Raising Health (a16z Bio + Health)
The venture capital view, hosted by Andreessen Horowitz's bio and health team, including general partners Vijay Pande and Julie Yoo. Useful precisely because it's the unapologetic bull case: where investors believe AI, telehealth and consumer health are going, told by the people funding it. Their episodes on AI entering clinical workflows — scribing, triage, diagnostics — map the next five years of the industry, accurately or not.
Digital Health Today
Dan Kendall's long-running show is broader and more international than the US-centric names above: health systems, remote patient monitoring, digital therapeutics and how other countries are absorbing the same technology with different incentives. The right listen for understanding that the American DTC boom is one version of this story, not the only one.
The fault line the shows keep returning to
The optimist case is access, and it's real: people in rural areas, people without sick leave, people priced out of therapy, men who would never book a urologist — telehealth reaches patients the old system structurally missed, and for routine, protocol-driven care the quality evidence is generally reassuring. The skeptic case, which Farr in particular presses hard, is incentives: when a company's revenue depends on the prescription being written, the consultation risks becoming a formality, and the marketing — podcast ads included, an irony the shows occasionally acknowledge — manufactures demand for medical treatment the way DTC industries manufacture demand for anything. Both cases are simply true at once, which is what makes the beat worth following rather than settling.
Where to start
If you're new to the beat, a sensible on-ramp: one Heart of Healthcare founder interview to understand the business mechanics, one Second Opinion episode on the GLP-1 prescribing fight to see the incentive problems up close, and one Raising Health episode on AI in care delivery to hear where the money believes this goes. Three hours, and you'll understand the industry better than most coverage of it. From there, follow the news cycle: each new controversy — a prescribing scandal, an FTC action, a compounding ruling — reliably produces the best episodes within a week or two, because this is one of the few health niches where the podcasters are genuine specialists rather than generalists reacting.
What to listen for in 2026
The threads these shows are tracking this year: AI moving from administrative work into triage and diagnosis, and the regulatory scramble around it; telehealth companies expanding from single products — hair, ED, weight — into full primary care and chronic disease management; the post-shortage GLP-1 settlement between drugmakers, compounders and telehealth platforms; insurers' uneasy relationship with DTC prescribing; and consolidation, as the pandemic-era startup glut resolves into a handful of category winners. Healthcare moving online was the easy prediction; who ends up owning the front door to medicine is the genuinely open question, and these are the shows where it gets argued in real time.
Related charts on Reason.fm: Medicine, Health & Fitness, and Tech News.